Skip to main content

Table 1 Baseline demographic, anthropometric and disease characteristics of study treatment groups

From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

  Omarigliptin N = 154 Placebo N = 153
Age, years 57.2 ± 8.4 58.4 ± 9.4
Female, n (%) 81 (52.6) 79 (51.6)
Race, n (%)
 White 116 (75.3) 110 (71.9)
 Asian 28 (18.2) 29 (19.0)
 Black 8 (5.2) 7 (4.6)
 Multi-racial 2 (1.3) 6 (3.9)
 Native Hawaiian or other Pacific Island 0 (0.0) 1 (0.7)
Ethnicity, n (%)   
 Not Hispanic or Latino 134 (87.0) 140 (91.5)
 Hispanic or Latino 14 (9.1) 5 (3.3)
 Not reported 2 (1.3) 3 (2.0)
Body Weight, kg 87.8 ± 18.3 85.4 ± 21.2
BMI, kg/m2 31.8 ± 6.2 30.6 ± 5.8
HbA1c, % 8.5 ± 0.8 8.6 ± 0.8
FPGa, mmol/L 10.1 ± 2.3 10.2 ± 2.3
Duration of type 2 diabetes, years 9.8 ± 5.3 10.4 ± 5.5
SU status at screening   
 Glimepiride 103 (66.9) 104 (68.0)
 SU other than glimepiride 51 (33.1) 49 (32.0)
  1. Values are mean ± standard deviation unless otherwise noted
  2. BMI body mass index, FPG fasting plasma glucose, SU sulfonylurea
  3. aTo convert to mg/dL multiply mmol/L value by 18